ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ CỦA PHÁC ĐỒ SOFOSBUVIR KẾT HỢP VELPATASVIR TRÊN NGƯỜI BỆNH VIÊM GAN VIRUS C MẠN TÍNH TẠI BỆNH VIỆN QUÂN Y 103 VÀ BỆNH VIỆN TRUNG ƯƠNG QUÂN ĐỘI 108 (TỪ THÁNG 5/2021 - 7/2024)

Abstract

Abstract

Objectives: Evaluation of treatment outcomes in patients with chronic hepatitis C using a Sofosbuvir–Velpatasvir regimen. Methods: This was a descriptive, longitudinal study combining both retrospective and prospective cohorts conducted from January 2021 to July 2024. A total of 40 patients who met the inclusion and exclusion criteria were treated at Military Hospital 103 and Central Military Hospital 108. Results: Clinical symptoms showed significant improvement at the end of treatment and 12 weeks post-treatment. Fatigue was reported in 80% of patients before treatment, which decreased to 20% at the end of treatment and 7.5% at 12 weeks post-treatment. Other clinical symptoms resolved completely by week 12 post-treatment. Elevated liver enzymes and bilirubin levels showed significant reductions at the end of treatment and 12 weeks after treatment. The proportions of patients with elevated AST, ALT, and total bilirubin levels before treatment were 77.5%, 87.5%, and 40%, respectively; these decreased significantly to 10%, 12.5%, and 12.5% by week 12 post-treatment. The sustained virological response at week 12 after treatment completion (SVR12) was achieved in all 40 patients (100%). Mild adverse effects of the treatment regimen were observed in a few cases: abdominal bloating (10%), headache and fatigue (5%), dizziness and insomnia (2.5%). No severe adverse events requiring discontinuation of treatment were recorded. Conclusion: Patients with chronic hepatitis C treated with the Sofosbuvir–Velpatasvir regimen demonstrated significant clinical improvement by the end of treatment and at 12 weeks post-treatment. The SVR12 rate reached 100%, indicating complete viral clearance. The regimen was well tolerated with no serious adverse effects requiring discontinuation.